- Anne Wojcicki
- CEO and Co-Founder
Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe now provides the only personal genetic test with FDA authorization to deliver health information directly to consumers.
From the beginning, Anne's goal and 23andMe’s mission has not wavered. Along with empowering consumers with health information, Anne wanted 23andMe to transform how research discoveries are made and revolutionize the development of treatments for disease. By inviting people to participate in research, 23andMe is able to crowdsource billions of data points resulting in the world’s largest resource for genetic research. This novel, web-based approach has already resulted in thousands of new genetic insights and allows 23andMe to rapidly recruit participants to multiple studies at once, reducing the time and resources needed to make discoveries and is integral to 23andMe’s mission of understanding and benefiting from the human genome This new approach to research also powers 23andMe’s therapeutics group, which is helping to translate this knowledge into new treatments for serious unmet medical needs. In line with this, 23andMe is now also using its unique model to speed recruitment for clinical trials.
Anne is a pioneer in the direct-to-consumer DNA testing space and her vision and persistence have allowed 23andMe to provide people with unprecedented access to genetic information. Through its research platform, 23andMe has brought personalized medicine directly to millions of consumers.
Anne graduated from Yale University with a BS in Biology.
- Kenneth Hillan, M.B., Ch.B.
- Chief Therapeutics Officer
Kenneth joined 23andMe in 2019 as Head of Therapeutics. He leads a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases.
At Achaogen, Hillan served as Chief Executive Officer. He held progressively senior roles at Genentech-Roche including Senior Vice President and Head of Clinical Development and Product Development Strategy Asia-Pacific for Roche in Shanghai, China. He led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair (ITGR) drug portfolio, and was responsible for numerous drug approvals.
Hillan is a member of the board of directors at Zymeworks. He served on the board of directors at Achaogen, and at Relypsa until it was acquired by Galenica AG in 2016.
He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from theFaculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). He has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
- Joyce Tung, Ph.D.
- Vice President, Research
- Kathy Hibbs, J.D.
- Chief Administrative Officer
- Steve Lemon
- Vice President, Engineering
- Tracy Keim
- Vice President, Consumer Marketing and Brand
Tracy joined 23andMe in 2013 to lead the company’s brand and product marketing efforts. She has extensive experience in integrated marketing, consumer insights and brand building. Tracy has focused on building and driving teams to develop advertising campaigns globally, balancing high impact ideas with realistic executions — while understanding the power of being data-driven.
Before joining 23andMe, Tracy’s experience came primarily from the agency and consulting-side, bringing a strategic framework to the creative and storytelling approach to building brands powered by consumers. Tracy has led and executed national and global brand campaigns combining immediate ROI and long-range strategy for Volvo Cars, 21st.com, Bonobos.com, Mercedes, E*TRADE, eHarmony.com, Bank of America and LegalZoom.com to name a few.
Tracy holds a Bachelor of Science in Advertising from the Newhouse School of Communications at Syracuse University and a Masters of Science in Integrated Marketing from Northwestern University.
- Arnab Chowdry, Ph.D.
- Vice President, Genetic Technology
Arnab joined 23andMe in 2009 and is the architect of 23andMe’s platform for processing genetic data. Among other duties, Arnab oversees the design and analytic validity of our genotyping technology.
Over the years he has been instrumental in several successful upgrades of our testing infrastructure, as well as ensuring that the data from new genotyping chips work seamlessly with 23andMe’s product and research platform. Before joining 23andMe, Arnab earned his Ph.D. in Biophysics from the University of California at Berkeley, where he studied computational protein design, and developed protein inhibitors for breast cancer metastasis with Dr. Tracy Handel. Before that received a SmileTrain grant for his work with Dr. Simeon Boyadjiev at the Johns Hopkins Children's Hospital to determine the disease-causing loci for rare genetic conditions such as oculodentodigital dysplasia.
Originally from Rochester, New York, Arnab has been interested in genetics since childhood.
- Katie Watson
- Vice President, Communications
Katie joined 23andMe in 2018 to lead the company’s internal and external communications efforts. In her role, Katie is responsible for driving the overall communications strategy and messaging for the company, with a focus on creative storytelling.
Prior to joining 23andMe, Katie spent 11 years helping lead product communications at Google, where she launched popular products like Google Photos and the Google Assistant. During her time there, she advised and worked closely with product leadership teams to build long-term narratives and create compelling media campaigns. Prior to Google, Katie was an Account Director and Partner at tech PR agency LEWIS PR.
She has a Bachelor’s Degree in Communication Studies with an emphasis in Media Relations, and minor in Business Administration from the University of San Diego.
- Mike Polcari
- Vice President, Chief Architect
Mike Polcari joined the company in 2008 helped build the team of engineers who develop the company’s core technology, and scale the research platform. Mike’s team is focused on architecture across 23andMe's commercial products, including the Personal Genome Service, Commercial Research Portal, and API platform.
Previously, he held engineering roles developing highly secure, scalable, intuitive applications at Salesforce.com and Merrill Lynch. His expertise has been leveraged to inform technical messaging needed to articulate the underlying system that powers and protects genetic information of 23andMe customers.
Mike holds a BS in Computer Science from Cornell University and a MS in Biomedical Informatics from Stanford University.
- Steve Schoch
- Chief Financial Officer
Steve joined 23andMe in 2018 as Chief Financial Officer, responsible for all aspects of the financial operations of the company, including accounting and controls, financial planning and analysis, tax planning and compliance, as well as funding,cash management and investor relations. Previously, Steve served as CEO of Miramax Films for five years while concurrently serving as CFO, a position he held from 2010. He led the building of a new studio company from the Miramax assets purchased from The Walt Disney Company in late 2010. During this period, Miramax built its distribution reach to 200 countries and re-launched its original content film and television development, and production and distribution capabilities. In 2016, Steve helped orchestrate the sale of Miramax to beIN Media Group.
Before joining Miramax, Steve held various senior financial roles at biopharmaceutical company Amgen, Inc., including Corporate Controller and divisional CFO, helping steward annual revenue growth from $3 billion to over $15 billion in less than ten years. Prior to that, he was Executive Vice President and Chief Financial Officer at eToys, Inc., a pioneering internet retailer of children’s products, where he led the company’s IPO, with an initial $8 billion market value.
Steve’s early career included a variety of financial positions in the media industry, including at The Walt Disney Company and the Times Mirror Company.
Steve holds a Bachelor of Science in Civil Engineering degree from Tufts University and a Master’s of Business Administration degree from the Tuck School of Business Administration, Dartmouth College.
- Fred Kohler
- Vice President, People
Fred Kohler joined 23andMe in 2019 as Vice President of People, focusing on company culture, training, and coaching.
With decades of experience leading human resources teams at biotech and pharmaceutical companies, Fred has developed specialties in organizational development and executive coaching. Before joining 23andMe, he served as Vice President of People at the biotechnology company, GRAIL. Prior to GRAIL, Fred worked at Roche/Genentech in a variety of roles leading global change and agility transformation work for the company.
Fred received an MBA from the Walter A. Haas School of Business at the University of California, Berkeley, and a Bachelor of Arts in English and Economics from Bucknell University. He is also a certified life coach.
- David Baker
- Chief Security Officer
David Baker joined 23andMe in 2020 as Chief Security Officer, overseeing IT & Security for the company and helping it set the industry standard for data privacy and security.
Over the last two decades, David built deep industry experience in creating secure systems and architecture. Before coming to 23andMe, he worked as the Chief Security Officer at Bugcrowd and Okta. David also spent time as the vice president of services for IOActive and was the security architect at Webex Communications. He started his career as a research scientist for NASA Ames, working on high-performance computational fluid dynamics simulations, a position that first sparked his interest in scientific computing.
David earned a bachelor’s degree in mechanical engineering at California State Polytechnic University-Pomona and his master’s degree in aeronautical engineering at California Polytechnic State University-San Luis Obispo. He is a competitive cyclist and runner.
- Jacquie Cooke Haggarty, J.D.
- General Counsel and Privacy Officer
Jacquie joined 23andMe in 2015 and is General Counsel and Privacy Officer. She is responsible for the development and execution of legal and compliance strategies and systems to support unprecedented innovation and access in consumer-driven health care. Leading 23andMe's data privacy policies and practices, Jacquie is passionate about disrupting the traditional healthcare system by putting consumers in control of their data and providing transparency around how their data is used.
Prior to 23andMe, she served as Senior Commercial Counsel at Genomic Health focused on international legal and health care compliance. Jacquie started her legal career at Latham & Watkins, working with a diverse portfolio of public and private companies on securities, employment, and general commercial litigation. Jacquie earned her J.D. from Georgetown University Law Center, her Master in Public Policy from Harvard Kennedy School, and her B.A. from U.C. Berkeley.
- Kumar Iyer
- Head of Product
Kumar joined 23andMe in January of 2018 and is Head of Product. He is responsible for overseeing the teams that develop and deploy new products and features at 23andMe. He’s excited to help our customers live better lives by understanding their genetics.
Previously, Kumar was the Head of Product and Engineering for PayJoy, focused on consumer lending in emerging markets. He also worked as a Mobile product lead at Facebook, helping to transition it to a mobile-first company with hundreds of millions of users. Kumar has also held engineering and product positions at Netflix, NVIDIA, and Electronic Arts and spends most of his free time chasing his two boys.
Kumar earned an MBA from UCLA’s Anderson School of Management and his undergraduate degree in Computer Science from UCLA.
- Jennifer Low, M.D., Ph.D.
- Head of Therapeutics Development
Jennifer Low joined 23andMe in 2018 as Head of Therapeutics Development. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies.
Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that, she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others.
She received her undergraduate degree from Caltech, her M.D. and Ph.D. degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program at NCI and an attending physician in breast cancer at the National Institutes of Health and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.
- Adam Auton, Ph.D.
- Vice President, Human Genetics
- Kent Hillyer
- Vice President, Customer Care
Kent Hillyer joined 23andMe in October 2013 and is currently Vice President, Customer Care.
He has overseen the growth of 23andMe’s exceptional Customer Care operation, managing teams spread throughout the world. The support operation is now rated ahead of companies such as Zappos and Nordstrom, according to established third-party benchmark platforms. Prior to coming to 23andMe, Kent worked as the Director of Customer Support, Training, and Commercial Operations at Ingenuity Systems where he served in various senior positions in operations, strategic planning, and process design.
Kent holds a Bachelor's Degree in Business Administration from Colorado State University and an MBA from the University of Denver.
- Monica Viziano, Ph.D.
- Vice President, Portfolio Strategy and Alliance Management
Monica Viziano joined 23andMe in 2020 as VP Portfolio Strategy and Alliance Management. She oversees the Business Development, Alliance Management, and Project Management groups.
Monica has considerable experience in the Pharmaceutical and Biotech Industry. She has participated in the development and commercialization of drugs across multiple therapeutic areas such as Inflammation, Oncology, HIV, HBV, CV, and CNS.
She worked at Gilead for 18 years. During her tenure at Gilead, she developed and maintained the most important and complex alliance collaborations. She was involved in the development of several drugs at Gilead, including TRUVADA, ATRIPLA, STRIBILD, and GENVOYA. Monica participated in several business development transactions, including in-licensing and partnerships with Japan Tobacco, ONO Pharmaceuticals, and Galapagos. Prior to joining Gilead, Monica worked at Schering-Plough and GSK.
Monica received her degree in Chemistry and Pharmaceutical Technologies at the University of Milan.
- D. Wade Walke, Ph.D.
- Vice President, Investor Relations
Wade joined 23andMe in 2021 to lead the company’s investor relations efforts. He has extensive background in developing and implementing strategic investor relations programs within the biotech space. He has dedicated his professional efforts toward working with companies that are striving to translate science into benefits for people in need.
Prior to joining 23andMe, Wade spent nine years at Ionis Pharmaceuticals, a leading company in RNA-targeted drug discovery and development, where he most recently served as Vice President of Investor Relations. During his time there, he was ranked as one of the top IR professionals three years in a row (2017–2019) by Institutional Investor magazine's "All-American Executive Team" (Biotechnology) rankings.
Prior to joining Ionis Pharmaceuticals, Wade also spent 13 years at Lexicon Pharmaceuticals, where he began as a Scientist and worked his way up to Associate Director of Bioinformatics in the Department of Functional Genomics. From there, he pivoted to lead Communications and Investor Relations for the company, a role in which he oversaw the implementation of a targeted program of IR activities. Wade holds a Bachelor of Science degree from Brigham Young University and Ph.D. and Master of Science degrees from the University of Michigan.
- Joseph R. Arron, M.D., Ph.D.
- Chief Scientific Officer
- Paul Johnson
- Chief Operating Officer, Consumer
Paul joined 23andMe in 2021 as part of the Lemonaid Health acquisition. Paul now leads the consumer teams and is focused on creating new and innovative personalized and preventative healthcare experiences founded on genetics.
Prior to 23andMe, Paul moved to the U.S. to be the co-founder and CEO of Lemonaid Health, a leading telehealth company launched in 2013. Lemonaid Health was the first direct to consumer telehealth service in the US and was the first company to provide access to birth control pills via a mobile app.
Prior to Lemonaid Health, Paul was Head of Online at Lloyds Pharmacy and Director, UK at Zooplus AG. He has a Bachelors of Science, with honors in IT and Business Management from the University of Worcester in the UK.
- Jeff Brown
- Vice President, Financial Planning and Analysis
Jeff Brown joined 23andMe in 2022 as the company’s Head of Financial Planning & Analysis (FP&A).
Prior to 23andMe, Jeff spent over 18 years at Amgen in various roles within the Finance organization. Jeff held several leadership positions at Amgen, including 13 years across R&D FP&A and Commercial FP&A. Most recently, he was the project lead in successfully delivering on a large procure-to-pay transformation initiative.
Jeff has over 25 years of experience in Accounting and Finance across biotech and consumer products. Jeff began his career spending four years in Audit at Ernst & Young, LLP. He then moved to the consumer products industry prior to joining Amgen.
Jeff received his Bachelor of Arts in Business Administration from the University of Washington. He is also a Certified Public Accountant (Inactive).